



Sanofi Innovation Awards iAwards

Sanofi iAwards: Call-for-Proposals

9UW 'gY`YVWX`J5k UfX`dfc`YVWk J`fYVW`j Y.

- ÁFGÍ ÉÉÉÁ•^æ&@ } āā * Á & āā * Á • Ą Ą } āā āā^&@ • • DĀ | ÁGĀ [] c@
- Ûā [-Á &ā } āāÁĉ] ^ | ĉ ^ Ē ^ āāāē āĀ | [b &Ā } āā^ { ^ } Ā ~] [| āā āāÁ &ā } āāÁ&@] ā }
- QĒ ā āÁ• [~ | &• Á ~ &@ē Á ^ āē } • Ē [| & {] [~ } ā • Ē āēĒā^ { ^ āĀ ^ &•• āē Áē āāāē & Á @Ā | [b &c
- Û &•• ~ | Ā | [b &• & ~ | āā^ & } ĉ ^ ĉ āĀ ÁÜČē āā āā & ā ^ āāāāā } āĀ } āā * Á | ÁĒĀ ^ āē

Areas of Interest

Sanofi is seeking the following type of opportunities in the therapeutic areas provided below:

- Early stage compounds, small molecules or biologics targeting novel disease mechanisms
- Disease relevant targets with validated mechanism of action
- Technology platforms with the potential to significantly improve drug discovery and development (examples – gene therapy, biologics development)
- Novel therapeutic modalities

■ IMMUNOLOGY & INFLAMMATION

- Diseases associated with dysregulated Type 2 immune responses including Atopic Dermatitis and Asthma
- Type 1/17 immune responses and Rheumatological disorders including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, and IBD
- Autoimmune sequelae of checkpoint inhibition
- Co-stimulation and co- inhibitory pathways in autoimmune and allergic diseases
- Immune tolerance, organ-specific autoimmunity and emerging immunotherapies for autoimmune disease.
- Systems and computational immunology
- Immuno-metabolism

■ IMMUNO-ONCOLOGY

- Mechanisms of innate and acquired resistance to checkpoint blockade
- Immuno-modulatory function of CD38
- Immuno-modulatory function of TGFb
- Immune cell engagers (NK cells & T cells engagers)
- Immuno-conjugates
- Novel ADC targets
- Intra-tumoral Treg depletion, modulation of immunosuppressive myeloid lineages
- Immune profiling methodologies in preclinical and clinical setting
- Novel translational models in IO

■ MOLECULAR ONCOLOGY

Sanofi priority indications are breast, lung, multiple myeloma, prostate but also could be other cancers pending on target or modality

- Novel targets and/or early drug discovery projects in molecularly-defined cancer populations and/or lineage
- Tumor induced immune-suppression: regulation of anti-tumor immunity when the target is located in tumor cells
- Tumors microenvironment targeting programs
- Modality: targeted protein degradation (PROTAC, Glue, monovalent degrader)

**The deadline for submission
is June 10th, 2020.**